PET/CT Scan for Pheochromocytoma and Paraganglioma
Part of Cancer clinical trials.
This trial uses a special PET/CT scan called Al18F-NOTA-LM3 to help doctors see pheochromocytoma and paraganglioma tumors more clearly. It may help find out if you have these tumors and guide your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a suspected or confirmed pheochromocytoma or paraganglioma (a type of rare tumor that can affect hormone levels).
- You do not have any other types of tumors.
- You do not have severe liver or kidney problems.
- You are not pregnant or breastfeeding.
- You are able to have a PET/CT scan (lie still for about 30 minutes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial uses a special PET/CT scan to help evaluate neural crest tumors, which include conditions like neuroblastoma. It may help doctors understand how well the scan shows tumor activity to guide diagnosis and treatment planning.
This study compares a new imaging agent (Al18F-NOTA-LM3) with two existing ones (68Ga-DOTATATE and 68Ga-NODAGA-LM3) during PET/CT scans to see if it's better at finding well-differentiated neuroendocrine tumors. Participating may help improve how these tumors are detected.
This study uses a special PET/CT scan to look at the environment around your lymphoma. The goal is to see if this scan can predict how well your treatment will work and your long-term outcome.
This trial looks at using a specific PET/CT scan (a whole-body imaging test) to help evaluate cancer that is confirmed or suspected. If you are eligible, you may receive this scan soon after a recent FDG PET/CT to compare or improve how cancers are identified.
This trial tests a new PET/CT scan (using a tracer called Al18F-NOTA-LM3) to better find tumors causing TIO, a condition that leads to bone softening and weakness. It may help doctors diagnose and treat TIO more accurately.
This early study uses a special PET/CT scan to see how much a specific cancer-related protein (PARP-1) is present in pheochromocytoma and paraganglioma. It may help doctors understand the biology of these tumors and how useful this scan could be in the future.
Hear when a new Pheochromocytoma/Paraganglioma (PPGL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.